Zydus Cadila gets USFDA approval for schizophrenia drug

HOME » BUSINESS » HEALTHCARE » Zydus Cadila gets USFDA approval for schizophrenia drug

Pharmaceutical manufacturer Zydus Cadila said it received final approval from the United States Food and Drug Administration for sales of a generic version of Sunovion Pharmaceuticals’ Latuda tablets.

Lurasidone tablets are used to treat certain conditions associated with bipolar disorder such as schizophrenia and depression. It also helps to decrease hallucinations.

The drug will be sold in doses of 60 mg, 80 mg and 120 mg.

The tablet will be manufactured at the company’s facility in Ahmedabad.

With the latest nod, the company has so far received 257 approvals and filed over 350 applications for the sales of its generic drugs.

Headquartered in Ahmedabad, Zydus Cadila has manufacturing sites and research facilities across Gujarat, Maharashtra, Goa, Himachal Pradesh and Sikkim and even in the United States and Brazil.

(Now you can get topic-based alerts via WhatsApp)


Sign up to get the latest Pharma-related news delivered via email:

Don't forget to click on the activation link we send to your email